Study on Loncastuximab Tesirine and Rituximab Before CAR T-cell Therapy for Large B-cell Lymphoma

Inclusion Criteria

• Must be 18 years or older.
• Planned to receive standard CD19-directed CAR T-cell therapy.
• Need additional treatment before CAR T-cell therapy as decided by the doctor.
• Have large B-cell lymphoma that has returned or not responded to at least one previous treatment.
• Have measurable disease as shown by specific imaging tests.
• Be in relatively good health with an ECOG performance status of 0 to 2.
• Meet specific time requirements between previous cancer treatments and the first dose of the study drugs.
• Have adequate organ function, including specific blood counts and liver and kidney function.
• Women must not be pregnant and must meet certain criteria if they are of childbearing potential.
• Agree to use effective contraception if of childbearing potential.
• Be able to understand and sign an informed consent form.

Exclusion Criteria

• Have had previous treatment with any anti-CD19 therapy or CAR T-cell therapy.
• Are receiving investigational CAR T-cell products.
• Have had major surgery within 4 weeks before starting the study.
• Have a history of bleeding disorders or active bleeding.
• Have severe liver disease.
• Are pregnant, breastfeeding, or planning to become pregnant during the study.
• Have active graft-versus-host disease.
• Have certain autoimmune diseases or other cancers that may affect safety or participation.
• Have known involvement of the central nervous system by lymphoma.
• Have significant medical conditions that could increase risks or affect participation.
• Have active infections requiring treatment at the time of screening.
• Have HIV infection.
• Have active hepatitis B or C infections unless specific conditions are met.
• Have severe allergies to study drugs or their components.
• Are taking medications that are not allowed during the study.